Chrysalis Biotherapeutics
Saving Lives
Through Innovation
Chrysalis is pioneering the use of natural regenerative peptides to restore vascular function and activate normal stem cell populations where they exist in the body to accelerate tissue repair and prevent damaging effects of trauma, disease, ischemia, and radiation exposure
Solution for Radiation Induced Tissue Damage
Development of drugs to selectively reduce radiotherapy-induced normal tissue damage may improve post-therapy quality of life and save lives.
Solution for Nuclear Radiation Exposure
A single TP508 injection 24 hours after a lethal dose of whole body radiation significantly increases survival and reduces delayed effects of radiation.
TP508 Peptide Technology
The TP508 thrombin peptide is released locally following vascular injury to initiate cellular regenerative processes that lead to revascularization, stem cell activation, and tissue repair.
Regenerative Medecine
Chrysalis BioTherapeutics is developing a “next generation” therapeutic approach that harnesses the body’s natural regenerative signals to protect and activate endogenous progenitor stem cells.
Clinical Pipeline
Latest Press Releases
Drug developed by Galveston scientist to be tested for COVID-19 use
GALVESTON A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems related to COVID-19, thanks to
TP508 Mitigates Radiation Induced GI Damage
Kantara, C., Moya, S.M., Houchen, C.W., Umar, S., Ullrich, R.L., Singh, P. and Carney, D.H. (2015) Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department
Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508
GALVESTON, Texas, Aug. 21, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European
